NCT01899638View on ClinicalTrials.gov

Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 20, 2013

Primary Completion Date

July 25, 2013

Study Completion Date

July 25, 2013

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

UMEC/VI 125/25 mcg

Combination in high dose

DRUG

UMEC/VI 62.5/25 mcg

Combination in low dose

DRUG

UMEC 125 mcg

LAMA mono in high dose

DRUG

UMEC 62.5 mcg

LAMA mono in low dose

DRUG

VI 25 mcg

LABA mono

Trial Locations (1)

200030

GSK Investigational Site, Shanghai

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01899638 - Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study. | Biotech Hunter | Biotech Hunter